Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

The S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

The FDA and EMA will now look at the results and see if the mRNA-based vaccine can be given a green light for widespread use, and according to Moderna the data will be discussed at a meeting of ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...

Moderna (NASDAQ: MRNA ... a phase 3 trial for a norovirus vaccine candidate that could produce efficacy data this year, depending on how rapidly new cases of the wintertime stomach bug accrue.

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.

Moderna and Merck have reported positive data for mRNA-4157 in a phase 2 melanoma trial, and we assume a 60% probability of success and multi-billion-dollar sales potential, with even higher ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...